ArticleScience immunology2019
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- Prognostic Value of Tumor-Infiltrating Lymphocytes Differs Depending on Lymphocyte Subsets in Esophageal Squamous Cell Carcinoma: An Updated Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Clinical efficacy and safety evaluation of Buzhongyiqi pills on appetite improvement in patients with colorectal cancer receiving chemotherapy: a pilot randomized cross-over clinical trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Trial
- Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma.Cancer research communications · 2026Article
- ENO1 as an Immunoregulatory Hub in Cancer: Mechanisms and Translational Implications.Biomolecules · 2026Review
- Transcriptional and functional profiling reveals unique activation of Adapter CAR T cells in acute myeloid leukemia.Journal of translational medicine · 2026Article
- CFD overexpression inhibits CESC progression and enhances TIL therapy efficacy via NOSTRIN and eNOS signaling pathway.Scientific reports · 2026Article
- Poorly perfused tumor regions harbor T cells with a glucose-dependent effector phenotype.EMBO reports · 2026Article
- The role of tumor metabolic reprogramming in acquired anti-PD-1/PD-L1 resistance.Translational lung cancer research · 2026Review
- Metabolic and transcriptional plasticity supports CD8Immunity · 2026Article
- Targeting ANXA1/TRKA axis enhances immunotherapy sensitivity in neural invasion-positive gastric cancer.Molecular biomedicine · 2026Article
- Compartment-specific GLUT1 patterns in colorectal liver metastases: invasive-margin GLUT1 associates with outcome in solitary disease.Cancer immunology, immunotherapy : CII · 2026Article
- Mitochondria in T‑cell tumor immunity and tumor therapies targeting mitochondria (Review).Oncology reports · 2026Review
- Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives.Journal of translational medicine · 2026Review
- Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape.Nature reviews. Immunology · 2026Review
- Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion.International journal of nanomedicine · 2026Review
- Combination of albumin-lymphocyte score and skeletal muscle index predicts prognosis of patients with ovarian cancer after primary debulking surgery.Frontiers in immunology · 2026Article
- Metabolic heterogeneity in tumor cells impacts immunology in lung squamous cell carcinoma.Oncoimmunology · 2025Article
- ENO2 regulates CD4mBio · 2025Article
- Mitochondrial Regulation of CD8⁺ T Cells: Mechanisms and Therapeutic Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- ENO1-BACE2-mediated LDLR cleavage promotes liver cancer progression by remodelling cholesterol metabolism.Journal of molecular cell biology · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 4 countries.
Lelisa F GemtaDepartment of Pathology, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0001-8234-1738
Peter J SiskaDepartment of Internal Medicine III, University Hospital Regensburg, 93053 Regensburg, Germany.ORCID 0000-0002-1521-6213
Marin E NelsonDepartment of Pharmacology, University of Virginia, VA 22908, USA.
Xia GaoDepartment of Pharmacology and Cancer Biology, Duke University, NC 27710, USA.ORCID 0000-0003-0979-9990
Xiaojing LiuDepartment of Pharmacology and Cancer Biology, Duke University, NC 27710, USA.ORCID 0000-0002-4231-6017
Jason W LocasaleDepartment of Pharmacology and Cancer Biology, Duke University, NC 27710, USA.ORCID 0000-0002-7766-3502
Hideo YagitaDepartment of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
Craig L SlingluffDepartment of Surgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA.ORCID 0000-0002-6664-4373
Kyle L HoehnSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Jeffrey C RathmellDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Timothy N J BullockDepartment of Pathology, University of Virginia, Charlottesville, VA 22908, USA. TB5V@virginia.edu.ORCID 0000-0001-6141-3261
Duke University · USUniversity of Virginia · USJuntendo University · JPUniversity Hospital Regensburg · DEUniversity of Virginia Health System · USUNSW Sydney · AUVanderbilt University Medical Center · US
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1MINTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2MExploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory diseaseR01DK105550 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2015 to 2026
$4.7MMetabolic Barriers to T Cell Activation in Clear Cell Renal Cell CarcinomaR01CA217987 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2018 to 2026
$4.3MBLIMP-1 mediated regulation of CD8+ TILR01CA166458 · NCI · UNIVERSITY OF VIRGINIA · PI BULLOCK, TIMOTHY N · 2013 to 2017
$2.9MData commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598kHigh-Performance Computer Cluster for Biomedical ResearchS10OD023680 · OD · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2017 to 2017
$587kLSM880-Airyscan Confocal Microscope for Large Shared ResourceS10OD021630 · OD · VANDERBILT UNIVERSITY · PI WELLS, K. SAM · 2016 to 2016
$560kNCI NIH HHS P30 CA044579NCI NIH HHS R01 CA166458NCI NIH HHS R01 CA217987NIAID NIH HHS T32 AI007496NIDDK NIH HHS R01 DK105550NIH HHS S10 OD018164NIH HHS S10 OD021630NIH HHS S10 OD023680
Abstract
In the context of solid tumors, there is a positive correlation between the accumulation of cytotoxic CD8
Indexed as
AnimalsAntineoplastic Agents, ImmunologicalCD8-Positive T-LymphocytesCell Line, TumorGlucoseGlucose Transporter Type 1GlycolysisHepatitis A Virus Cellular Receptor 2HumansImmunoglobulin GImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingMelanomaMice, Inbred C57BLPhosphopyruvate HydrataseProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalGlucoseGlucose Transporter Type 1Havcr2 protein, mouseHepatitis A Virus Cellular Receptor 2Immunoglobulin GPdcd1 protein, mousePhosphopyruvate HydrataseProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.